ImmunoGen to Present Preclinical Data on IMGN151 at AACR Virtual Annual Meeting
15 May 2020 - 2:01PM
Business Wire
Next Generation Anti-FRα ADC Demonstrates Potent Anti-Tumor
Activity in Ovarian Cancer Models and Other FRα-positive Tumor
Types in Preclinical Studies
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced preclinical data for its next generation
anti-folate receptor alpha (FRα) ADC, IMGN151, which is being
investigated in tumors with a broad range of FRα expression. The
data will be shared via poster presentation at the virtual American
Association for Cancer Research (AACR) Annual Meeting II being held
June 22-24, 2020.
“To address the unmet needs of additional patient populations,
we sought to develop a FRα-targeting ADC active against ovarian
cancer and other tumor types with a broad range of FRα expression.
IMGN151 demonstrates our continued innovation in the field of ADCs,
incorporating several key design elements including a novel
biparatopic antibody that enhances binding with FRα and payload
delivery as well as DM21, our most advanced maytansinoid derivative
that, together with a peptide linker, provides improved stability
and increased bystander anti-tumor activity,” said Eric Westin, MD,
Vice President, Clinical Development and Translational Sciences for
ImmunoGen. “In preclinical models, IMGN151 showed activity not only
in high FRα-expressing tumors, but also improved activity in medium
and low FRα-expressing tumors, suggesting promising potential in a
broad set of patients with an array of tumor types. As we continue
to analyze these data, we look forward to advancing IMGN151 into
preclinical development.”
PRECLINICAL DATA ON IMGN151 IMGN151 comprises an
asymmetric, bivalent, biparatopic antibody targeting two
independent epitopes of FRα, linked to a highly potent maytansinoid
derivative, DM21, via a cleavable peptide linker with enhanced
stability, longer half-life, and increased bystander activity. The
average drug per antibody ratio is 3.5.
Key findings include:
- IMGN151 activity was characterized against cell lines and
xenograft models with a wide range of FRα expression and compared
to mirvetuximab soravtansine (IMGN853). Cell lines and xenograft
models originated from ovarian, endometrial, breast, and cervical
cancer.
- In tumor cells with medium and high FRα expression, IMGN151
boosted antibody binding events and payload delivery by 100% and
170%, respectively.
- IMGN151 increased ADC half-life by 60 hours and conjugate
exposure in vivo by 40%, as compared to IMGN853.
- In vitro, IMGN151 was up to 200 times more active against four
FRα-medium cell lines. IMGN151 also had better bystander killing
activity in a mixed culture of target-positive and negative
cells.
- In vivo, IMGN151 induced complete tumor regressions of human
tumor xenograft models with high, medium, and low FRα expression.
All tested doses were well tolerated.
POSTER PRESENTATION
- Title: “IMGN151: A Next Generation Folate Receptor Alpha
Targeting Antibody Drug Conjugate Active Against Tumors with Low,
Medium, and High Receptor Expression”
- Day/Time: Monday, June 22, 2020 at 9:00 AM ET
- Session Category: Experimental and Molecular
Therapeutics
- Session Title: Antibody Drug Conjugates
- Abstract: 2890
Additional information can be found at www.aacr.org.
ABOUT IMGN151 IMGN151 is a next-generation ADC, designed
to address the unmet needs of cancer patients with tumor types
expressing lower levels of folate receptor alpha (FRα). IMGN151
comprises an asymmetric, bivalent, biparatopic antibody targeting
two independent epitopes of FRα, linked to a highly potent
maytansinoid derivative, DM21, via a cleavable peptide linker with
enhanced stability, longer half-life, and increased bystander
activity.
ABOUT IMMUNOGEN ImmunoGen is developing the next
generation of antibody-drug conjugates (ADCs) to improve outcomes
for cancer patients. By generating targeted therapies with enhanced
anti-tumor activity and favorable tolerability profiles, we aim to
disrupt the progression of cancer and offer our patients more good
days. We call this our commitment to “target a better now.”
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
FORWARD LOOKING STATEMENTS This press release includes
forward-looking statements based on management's current
expectations. These statements include, but are not limited to,
ImmunoGen’s expectations related to: the occurrence, timing, and
outcome of potential pre-clinical, clinical, and regulatory events
related to ImmunoGen’s product candidates; and the presentation of
pre-clinical and clinical data on ImmunoGen’s product candidates.
For these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. Various factors could
cause ImmunoGen’s actual results to differ materially from those
discussed or implied in the forward-looking statements, and you are
cautioned not to place undue reliance on these forward-looking
statements, which are current only as of the date of this release.
Factors that could cause future results to differ materially from
such expectations include, but are not limited to: the timing and
outcome of ImmunoGen’s pre-clinical and clinical development
processes; the difficulties inherent in the development of novel
pharmaceuticals, including uncertainties as to the timing, expense,
and results of pre-clinical studies, clinical trials, and
regulatory processes; ImmunoGen’s ability to financially support
its product programs; risks and uncertainties associated with the
scale and duration of the COVID-19 pandemic and resulting impact on
ImmunoGen’s industry and business; and other factors more fully
described in ImmunoGen’s Annual Report on Form 10-K for the year
ended December 31, 2019 and other reports filed with the Securities
and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200514005906/en/
INVESTOR RELATIONS AND MEDIA CONTACTS ImmunoGen Courtney
O’Konek 781-895-0600 courtney.okonek@immunogen.com
OR
FTI Consulting Robert Stanislaro 212-850-5657
robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2024 to May 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From May 2023 to May 2024